ATOS Key Statistics, Chart & Performance
The current stock price of ATOS is 0.6306 USD. In the past month the price decreased by -14.61%. In the past year, price decreased by -37.56%.
ATOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About ATOS
Company Profile
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 13 full-time employees. The company went IPO on 2012-11-08. The company is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. The company is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. The company has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Company Info
ATOSSA THERAPEUTICS INC
1448 NW MARKET STREET, SUITE 500
Seattle WASHINGTON 98104 US
CEO: Steven C. Quay
Employees: 15
Phone: 12065880256
ATOSSA THERAPEUTICS INC / ATOS FAQ
What does ATOS do?
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 13 full-time employees. The company went IPO on 2012-11-08. The company is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. The company is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. The company has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Can you provide the latest stock price for ATOSSA THERAPEUTICS INC?
The current stock price of ATOS is 0.6306 USD. The price increased by 6.88% in the last trading session.
What is the dividend status of ATOSSA THERAPEUTICS INC?
ATOS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ATOS stock?
ATOS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for ATOSSA THERAPEUTICS INC?
ATOSSA THERAPEUTICS INC (ATOS) currently has 15 employees.
Can you provide the upcoming earnings date for ATOSSA THERAPEUTICS INC?
ATOSSA THERAPEUTICS INC (ATOS) will report earnings on 2026-03-23, after the market close.
ATOS Technical Analysis
ATOS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ATOS. No worries on liquidiy or solvency for ATOS as it has an excellent financial health rating, but there are worries on the profitability.
ATOS Financial Highlights
Over the last trailing twelve months ATOS reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS increased by 4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.02% | ||
| ROE | -60.62% | ||
| Debt/Equity | 0 |
ATOS Forecast & Estimates
10 analysts have analysed ATOS and the average price target is 5.87 USD. This implies a price increase of 830.07% is expected in the next year compared to the current price of 0.6306.